11月12日，博安生物(06955)盘中下跌6.9%，截至10:38，报8.5元/股，成交122.97万元。
山东博安生物技术股份有限公司是一家生物制药公司，主要业务包括生物药开发、生产和商业化，特别专注于肿瘤、自身免疫、眼科和代谢疾病领域。目前，公司拥有三款商业化产品，已在中国及包括欧美在内的海外市场进行生物药产品开发，并有几个在研的创新生物药和生物类似药产品组合，已构建起全覆盖“研发-生产-商业化”的产业价值链运营体系。
截至2024年中报，博安生物营业总收入3.63亿元、净利润6167.2万元。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.